Education

Satellite Meetings


The events listed below are not part of the official ASAM Annual Conference as planned by its Program Committee.  Attendance is optional, and in some cases, there is limited seating. 

There will be nine satellite meetings adjunct to the ASAM Annual Conference. Please take a look at the events listed below.

Changing the Narrative in the Treatment of Opioid and Alcohol Dependence

 

Friday April 7, 2017

8:00 pm – 9:30 pm

Hilton New Orleans Riverside, Grand Salon B, First Level

 

SPONSORED BY ALKERMES

 

PROGRAM DESCRIPTION:

This evening presentation focuses on changing the way we look at the treatment of opioid and alcohol Dependence. Dr Bailey will discuss how opioids and alcohol affect the brain potentially leading to dependence and an in-depth review of one Medication-Assisted Treatment (MAT) option. No CME credits are available for this presentation.

 

FACULTY:

Genie L. Bailey, M.D. Diplomate, American Board of Addiction Medicine, Clinical Associate Professor of Psychiatry and Human Behavior Warren Alpert Medical School of Brown University, Director of Research & Medical Director of Dual Diagnosis Unit Stanley Street Treatment & Resources

 


A Different Approach for the Long-Term Treatment of Opioid Use Disorder

 

Friday April 7, 2017

8:00 pm – 9:30 pm

Hilton New Orleans Riverside, Grand Salon C, 1st Floor

 

SPONSORED BY BRAEBURN PHARMACEUTICALS

 

PROGRAM DESCRIPTION:

The treatment of opioid use disorder long-term with medication has been shown to be an effective approach to this chronic brain disease.  Medication assisted treatment has shown to reduce the risk of death by 85% when used for at least 12 months.   The product theater will focus on the benefits of long-term treatment of opioid use disorder including data from a recent publication in JAMA.

 

FACULTY: 

Stuart Gitlow, MD, MPH, MBA, DFAPA

Dr. Gitlow is Executive Director of the Annenberg Physician Training Program in Addictive Disease at Mount Sinai School of Medicine in New York, NY, which he started in 2005 to ensure medical student access to training that stimulates them to develop and maintain interest in working with patients with addiction. He serves as the Past President of the American Society of Addiction Medicine, and as ASAM’s Delegate to the American Medical Association’s House of Delegates. Dr. Gitlow is the former Chair of the AMA Council on Science and Public Health.

Dr. Gitlow is on faculty at the University of Florida. His educational training took place at Massachusetts Institute of Technology, Mount Sinai School of Medicine, University of Pittsburgh Medical Center, and at Harvard Medical School. He formerly produced Health programming for ABC Television and America Online.

 

Michael P. Frost MD, FACP, FASAM

President – The Frost Medical Group

Medical Director – Eagleville Hospital

Dr. Michael Frost is a nationally recognized specialist in treatment of addictive diseases. Board certified in both Addiction Medicine and Internal Medicine, he is a fellow of The American Society of Addiction Medicine, fellow of The American College of Physicians and a member of The Canadian Society of Addiction Medicine. He currently serves as Medical Director for Eagleville Hospital, a 306-bed inpatient substance abuse treatment facility in Norristown Pa. He is also President and Medical Director of The Frost Medical Group, LLC, a PA Dept. of Health accredited outpatient addiction treatment clinic. In addition to his work with patients, Dr. Frost is also heavily involved in conducting clinical research trials, and consults with numerous companies regarding clinical development and healthcare policy. He frequently lectures across the United States and internationally and has made numerous media appearances. 

 

Ole W. Snyder, MD

Dr. Snyder is a Family Medicine physician and Dermatologic Surgeon at Scripps Health in San Diego and has championed physician education as a UCSD Clinical Instructor of resident physicians since 1998.  He has consulted and contributed to the development, launch, commercialization, and training of multiple novel drug delivery procedures and is a Senior Master Trainer for the Probuphine REMS program. Dr. Snyder has lectured nationally and internationally on opioid epidemic topics, advocating for physician development and awareness of evolving standards of care and novel treatments.  Dr. Snyder is a member of the American Society of Addiction Medicine, American Academy of Family Physicians, and the American Association for Primary Care Endoscopy.

[1] Risk of death during and after opiate substitution treatment in primary care: prospective observational study in UK General Practice Research Database.Cornish R, Macleod J, Strang J, Vickerman P, Hickman M. BMJ. 2010 Oct 26;341:c5475. doi: 10.1136/bmj.c5475


START: HIV

Screen, Talk, Assess, Refer, Treat

 

 Friday, April 7, 2017

8:00 pm - 9:30 pm 

Hilton New Orleans Riverside, Room: Grand Salon A, First Level

 

SPONSORED BY GILEAD SCIENCES, INC. AND JOINTLY PROVIDED BY POSTGRADUATE INSTITUTE FOR MEDICINE AND DKBMED, LLC.

 

Stories are a part of being human; they’re the way we organize our brains. This is why the famous TED talks appeal to millions of people: they employ our most potent tools of memory and imagination to expand our minds. 

We are now making this engaging format available to health care providers. DKBmed Talks –Screen, Talk, Assess, Refer, Treat (START: HIV) addresses vital topics in screening patients at risk for HIV, the use of prophylactic therapy, and the importance of referring patients with HIV to specialist care. Our expert faculty share their most poignant stories – the patients who made them appreciate why they chose to practice medicine. In addition, all the scientific and clinical detail will be provided in a way you have never seen before.

During this symposium hear how we will tackle:

•           The shifting demographic of new HIV cases

•           The challenges presented by the opioid epidemic

•           Whom to screen: identifying risk factors

•           When to use PrEP

•           Benefits of newer therapies

•           Single-pill regimens

•           Minimizing adverse events

Register now at www.startHIV.dkbmed.com

 


 

Solve Any Problem in Addiction with TOC

Friday, April 7, 2017

8:00 pm - 9:30 pm 

Hilton New Orleans Riverside, Grand Salon D, First Level

 

SPONSORED BY DR. HOWARD WETSMAN, MD, DFASAM

In 2009, Howard Wetsman and Michael Handley bought 5 addiction treatment clinics in Louisiana for less than $50,000. They turned them around, became profitable, expanded, and developed an advanced proprietary treatment system that showed superior results. Seven years later they sold that company for over $20 million dollars. They did that with the tools developed within The Theory of Constraints (TOC). During that experience these two partners used TOC to overcome several common problems in addiction treatment. Problems such as dealing with insurance companies, getting documentation compliance from counselors, reducing AMA rates, increasing engagement in treatment, and many others were all solved using the tools of TOC. Dr. Wetsman and Mr. Handley will provide an introduction to TOC and give the participants time to propose their own problems to see what the thinking tools of TOC can do.


Meet the Experts - Reception

 

Saturday, April 8, 2017

6:30 pm to 8:00 pm

Hilton New Orleans Riverside, Grand Salon A, 1st Floor

 

SPONSORED BY BRAEBURN PHARMACEUTICALS 

 

Program Description:

Join Braeburn as we host an evening reception.  Come and enjoy hor ‘oeuvres with beverages during our meet and greet.  

 


START: HCV

Screen, Talk, Assess, Refer, Treat

Saturday, April 8, 2017

6:30 pm – 8:00 pm

Hilton New Orleans Riverside, Room: Grand Salon C

 

SPONSORED BY GILEAD SCIENCES, INC. AND JOINTLY PROVIDED BY POSTGRADUATE INSTITUTE FOR MEDICINE AND DKBMED, LLC.

 

Stories are a part of being human; they’re the way we organize our brains. This is why the famous TED talks appeal to millions of people: they employ our most potent tools of memory and imagination to expand our minds.

We are now making this engaging format available to health care providers. DKBmed Talks – START Screen, Talk, Assess, Refer, Treat: HCV (START: HCV) addresses vital topics in screening patients at risk for HCV, new DAAs, and the importance of referring patients with HCV to specialist care. Our expert faculty share their most poignant stories - the patients who made them appreciate why they chose to practice medicine. In addition, all the scientific and clinical details will be provided in a way you have never seen before.

During this symposium hear how we will tackle:

•           Screening patients in the addiction care setting

•           Analyzing barriers

•           Adherence

•           Preventing HCV reinfection

•           New direct-acting antivirals (DAAs)

•           Therapies in development

•           Individualizing therapy for PWIDs

Register now at www.startHCV.dkbmed.com 

 


Bridging the Gaps for Patients

Saturday, April 8, 2017

6:30 pm – 8:00 pm

Hilton New Orleans Riverside, Room: Grand Salon D

 

SPONSORED BY GILEAD SCIENCES, INC.

 

Description: 

A promotional product presentation of Harvoni and Epclusa

Presenter:

Anthony Paul Albanese, MD, DFASAM


Treating Individuals With Opioid Use Disorder (OUD): Real-World Approaches to Common Challenges

 

Saturday, April 8, 2017

6:30 pm – 8:00 pm

Hilton New Orleans Riverside, Grand Salon B, First Level

 

SPONSORED BY INDIVIOR

 

Program Objective

Discuss clinical approaches to help address unmet needs and barriers to treatment for patients with OUD

 

Program Overview

Join us for an interactive dinner satellite symposium where we will discuss strategies to address challenges when treating patients with OUD. Our renowned panel will present information on disease education, various practice guidelines, barriers to treatment and unmet patient needs. You will discover approaches that may help improve access to care for OUD patients. 

 

Program Information

There is no pre-registration required for this program. Please plan to arrive 10 minutes before program start time because attendance is on a first come, first served basis.

Faculty Information

Moderator

Kenison Roy, MD, FASAM, FAACT

Medical Director, Addiction Recovery Resources, Inc. Residential Treatment Program, Metairie, LA

 

Faculty Presenters

Genie Bailey, MD, DABAM

Associate Clinical Professor of Psychiatry and Human Behavior, Brown University, Providence, RI

Director of Research and Medical Director of Dual Diagnosis Unit, Stanley Street Treatment and Resources, Inc., Fall River, MA

Michael Weaver, MD, FASAM

Professor, Department of Psychiatry and Behavioral Sciences, Medical Director, Center for Neurobehavioral Research on Addiction, University of Texas Health Sciences Center at Houston, Houston, TX


Buprenorphine Implant Training

  

Sunday, April 9, 2017

1:00 pm - 5:00 pm

Hilton New Orleans Riverside, Grand Salon C, First Level

 

SPONSORED BY BRAEBURN PHARMACEUTICALS

 

Braeburn Pharmaceuticals will be conducting a Buprenorphine Implant Training in New Orleans, LA on April 9, 2017 from 1:00pm-5:00pm.

Training is strictly limited to Physicians and Advanced Practice Providers (i.e., nurse practitioners and physician assistants).

Healthcare providers will be asked to review the REMS materials and the Full Prescribing Information before attending.

Due to the skills required for the procedure the healthcare provider must intend to implant in the immediate future on appropriate patients. Minimizing the time between training and implantation will avoid decay of the newly learned skill set.

No spouses or guests are permitted to attend any part of the training. 

**To learn more about our Buprenorphine Implant Training or to register, click the below link:

https://2017_Regional_REMS_Training

 **Please note that you will not be compensated to attend this training. You will need to travel to the closest regional location for training. Basic travel expenses may be reimbursed if Braeburn guidelines are followed. More details supplied on the registration link above.**

Important Safety Information (ISI)

INDICATIONS AND USAGE

PROBUPHINE contains buprenorphine, a partial opioid agonist. PROBUPHINE is indicated for the maintenance treatment of opioid dependence in patients who have achieved and sustained prolonged clinical stability on low-to-moderate doses of a transmucosal buprenorphine-containing product (i.e., doses of no more than 8 mg per day of Subutex or Suboxone sublingual tablet or generic equivalent).

PROBUPHINE should be used as part of a complete treatment program to include counseling and psychosocial support.

PROBUPHINE is not appropriate for new entrants to treatment and patients who have not achieved and sustained prolonged clinical stability, while being maintained on buprenorphine 8 mg per day or less of a Subutex or Suboxone sublingual tablet or generic equivalent.

 

 

WARNING: IMPLANT MIGRATION, PROTRUSION, EXPULSION and NERVE DAMAGE ASSOCIATED WITH INSERTION and REMOVAL

Risk Associated with Insertion and Removal

Insertion and removal of PROBUPHINE are associated with the risk of implant migration, protrusion, expulsion resulting from the procedure. Rare but serious complications including nerve damage and migration resulting in embolism and death may result from improper insertion of drug implants inserted in the upper arm. Additional complications may include local migration, protrusion and expulsion. Incomplete insertions or infections may lead to protrusion or expulsion.

Because of the risks associated with insertion and removal, PROBUPHINE is available only through a restricted program called the PROBUPHINE REMS Program. All Healthcare Providers must successfully complete a live training program on the insertion and removal procedures and become certified, prior to performing insertions or prescribing PROBUPHINE implants. Patients must be monitored to ensure that PROBUPHINE is removed by a healthcare provider certified to perform insertions.

CONTRAINDICATIONS

  • Hypersensitivity to buprenorphine or any other ingredients in PROBUPHINE (e.g., EVA). 
  • WARNINGS AND PRECAUTIONS 
  • Serious Complications from Insertion and Removal:Rare but serious complications including nerve damage and migration resulting in embolism and death may result from improper insertion of drug implants inserted in the upper arm. Additional complications may include local migration, protrusion and expulsion. Incomplete insertions or infections may lead to protrusion or expulsion. All Healthcare Providers must successfully complete a live training program on the insertion and removal procedures and become certified in the PROBUPHINE REMS program, prior to performing insertions or prescribing PROBUPHINE implants.
  • Addiction, Abuse and Misuse:Buprenorphine can be abused in a manner similar to other opioids. Monitor patients for conditions indicative of diversion or progression of opioid dependence and addictive behaviors. 
  • Respiratory and CNS Depression:Significant respiratory depression and death have occurred in association with buprenorphine particularly when taken by the intravenous (IV) route in combination with benzodiazepines or other CNS depressants (including alcohol). Consider dose reduction of CNS depressants when used concomitantly.
  • Neonatal Opioid Withdrawal Syndrome:Neonatal opioid withdrawal syndrome(NOWS) is an expected and treatable outcome of prolonged use of opioids during pregnancy.
  • Adrenal Insufficiency:If diagnosed, treat with physiologic replacement of corticosteroids, and wean patient off of the opioid.
  • Unintentional Pediatric Exposure:In the event an implant protrudes or comes out, keep the implant away from children. Buprenorphine can cause severe, possibly fatal, respiratory depression in children.
  • Risk of Opioid Withdrawal with Abrupt Discontinuation:If treatment is temporarily interrupted or discontinued, monitor patients for withdrawal and treat appropriately.
  • Risk of Hepatitis, Hepatic Events:Monitor liver function tests prior to initiation and during treatment. 
  • Risk of Withdrawal in Patients Dependent on Full Agonist Opioids:Verify that patient is clinically stable on transmucosal buprenorphine and not dependent on full agonists before inserting PROBUPHINE. 
  • Treatment of Emergent Acute Pain:Treat pain with a non-opioid analgesic whenever possible. If opioid therapy is required, monitor patients closely because higher doses may be required for analgesic effect.
  • Impairment of Ability to Drive and Operate Machinery:PROBUPHINE may impair the mental or physical abilities required for the performance of potentially dangerous tasks such as driving a car or operating machinery. 
  • Other systemic effects:PROBUPHINE may cause orthostatic hypotension in ambulatory patients. Buprenorphine, may elevate cerebrospinal fluid pressure and should be used with caution in patients with head injury, intracranial lesions, and other circumstances when cerebrospinal pressure may be increased. Buprenorphine can produce miosis and changes in the level of consciousness that may interfere with patient evaluation. Buprenorphine has been shown to increase intracholedochal pressure, as do other opioids, and thus should be administered with caution to patients with dysfunction of the biliary tract.
  • Infection at Implant Site:Infection may occur at the site of the insertion or removal. Excessive palpation may increase an opportunity for infection. Improper removal carries risk of implant-site infection. 
  • General Precautions:PROBUPHINE should be administered with caution in debilitated patients and those with myxedema or hypothyroidism; adrenal cortical insufficiency (e.g., Addison’s disease); CNS depression or coma; toxic psychoses; prostatic hypertrophy or urethral stricture; acute alcoholism; delirium tremens; or kyphoscoliosis. PROBUPHINE should also be administered with caution in patients with a history of keloid formation, connective tissue disease, e.g., scleroderma or history of recurrent MRSA infections.
  • Most common side effects of PROBUPHINE include:headache, insomnia, rhinorrhea, upper respiratory tract infection, nausea, anxiety, back pain, depression, constipation, and vomiting. 

PLEASE READ THE FULL PRESCRIBING INFORMATION, INCLUDING BOXED WARNING AND MEDICATION GUIDE, which you can access at http://www.probuphine.com/.

To report SUSPECTED ADVERSE REACTIONS, contact Braeburn at 1-844- 859-6341 or FDA at 1-800-FDA-1088 orwww.fda.gov/medwatch.